Seeking Alpha

Navidea Biopharmaceuticals (NAVB) enrolls the first subject in a Phase III trial for its NAV4694...

Navidea Biopharmaceuticals (NAVB) enrolls the first subject in a Phase III trial for its NAV4694 imaging agent, which is designed to identify whether patients have Alzheimer's disease, which can only be confirmed during autopsy. Yesterday, Navidea secured tens of millions of dollars in financing. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs